BGD Stock Overview
Biogened S.A. develops, produces, and distributes pharmaceutical products in Poland.
| Snowflake Score | |
|---|---|
| Valuation | 2/6 |
| Future Growth | 0/6 |
| Past Performance | 4/6 |
| Financial Health | 5/6 |
| Dividends | 2/6 |
Biogened S.A. Competitors
Price History & Performance
| Historical stock prices | |
|---|---|
| Current Share Price | zł25.00 |
| 52 Week High | zł32.60 |
| 52 Week Low | zł13.50 |
| Beta | 0.60 |
| 1 Month Change | -6.72% |
| 3 Month Change | 26.90% |
| 1 Year Change | 81.16% |
| 3 Year Change | 98.41% |
| 5 Year Change | 171.74% |
| Change since IPO | -37.50% |
Recent News & Updates
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations
Feb 21
Is Biogened (WSE:BGD) A Risky Investment?
Feb 01Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump
Feb 01Recent updates
Biogened's (WSE:BGD) Promising Earnings May Rest On Soft Foundations
Feb 21Is Biogened (WSE:BGD) A Risky Investment?
Feb 01Biogened S.A. (WSE:BGD) Looks Just Right With A 37% Price Jump
Feb 01We Think Biogened (WSE:BGD) Can Stay On Top Of Its Debt
Jun 30Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Oct 08Is Biogened (WSE:BGD) A Risky Investment?
Jun 29Does Biogened (WSE:BGD) Have A Healthy Balance Sheet?
Mar 25These 4 Measures Indicate That Biogened (WSE:BGD) Is Using Debt Reasonably Well
Dec 09Biogened (WSE:BGD) Has A Somewhat Strained Balance Sheet
Jul 29Biogened (WSE:BGD) Seems To Use Debt Quite Sensibly
Apr 30Is Biogened (WSE:BGD) A Risky Investment?
Jan 24Shareholder Returns
| BGD | PL Pharmaceuticals | PL Market | |
|---|---|---|---|
| 7D | 1.6% | 0.06% | 1.4% |
| 1Y | 81.2% | -3.1% | 26.6% |
Return vs Industry: BGD exceeded the Polish Pharmaceuticals industry which returned -3.1% over the past year.
Return vs Market: BGD exceeded the Polish Market which returned 26.6% over the past year.
Price Volatility
| BGD volatility | |
|---|---|
| BGD Average Weekly Movement | 14.8% |
| Pharmaceuticals Industry Average Movement | 4.8% |
| Market Average Movement | 5.1% |
| 10% most volatile stocks in PL Market | 9.8% |
| 10% least volatile stocks in PL Market | 3.1% |
Stable Share Price: BGD's share price has been volatile over the past 3 months.
Volatility Over Time: BGD's weekly volatility (15%) has been stable over the past year, but is still higher than 75% of Polish stocks.
About the Company
| Founded | Employees | CEO | Website |
|---|---|---|---|
| 2007 | 205 | Andrzej Grzegorzewski | www.biogened.pl |
Biogened S.A. develops, produces, and distributes pharmaceutical products in Poland. The company offers dermo-cosmetics under the Dermedic brand; and thermal water. It also exports its products.
Biogened S.A. Fundamentals Summary
| BGD fundamental statistics | |
|---|---|
| Market cap | zł61.41m |
| Earnings (TTM) | zł4.20m |
| Revenue (TTM) | zł95.56m |
14.6x
P/E Ratio0.6x
P/S RatioIs BGD overvalued?
See Fair Value and valuation analysisEarnings & Revenue
| BGD income statement (TTM) | |
|---|---|
| Revenue | zł95.56m |
| Cost of Revenue | zł32.09m |
| Gross Profit | zł63.47m |
| Other Expenses | zł59.27m |
| Earnings | zł4.20m |
Last Reported Earnings
Dec 31, 2023
Next Earnings Date
May 15, 2024
| Earnings per share (EPS) | 1.71 |
| Gross Margin | 66.42% |
| Net Profit Margin | 4.40% |
| Debt/Equity Ratio | 49.6% |
How did BGD perform over the long term?
See historical performance and comparison